Thermo Fisher Scientific
In the last decade, proteomics laboratories have been at the forefront of cutting edge biological research. Researchers have realized the importance of proteins and the roles that these biomolecules play as disease markers, drug targets, and therapeutic agents. Mass spectrometry core laboratories have democratized the field of proteomics by providing broad access to state-of-the-art instrumentation, enabling students, post-doctoral fellows, and faculty researchers to study protein pathways, characterize post-translational modifications, and profile protein expressions.
This webcast will feature two leading proteomics scientists—one at a university and one at a private sector proteomics facility—discussing the challenges that a core lab faces. They will provide insights on how to address these challenges, best practices for instrument performance, and tips for running successful core labs.
Allis Chien, PH.D., Director, Stanford University Mass Spectrometry, Stanford University
Allis Chien graduated from the University of San Francisco with a B.S. in Chemistry with an emphasis in Biochemistry. She earned her Ph.D. in Chemistry from Stanford University in 2000, then stayed on to establish and grow the Stanford University Mass Spectrometry (SUMS) core lab. SUMS encompasses both proteomics and small molecule applications, and annually serves approximately 150 PI labs. Dr. Chien is a member of ASMS and ACS, and serves on the Executive Board of the Association of Biomolecular Resource Facilities (ABRF).
Paul Taylor, Core Facility Manager, Rapid Novor, Inc.
Paul Taylor received an undergraduate degree from Memorial University of Newfoundland in medicine and did his graduate studies at the University of Calgary in infectious diseases. He began his proteomics career at Mt. Sinai Hospital in Toronto and left to join the newly formed company MDS Proteomics in 2000. He worked as a scientist and principal investigator and became Director of Operations for Protana Analytical Services, a spin-off or MDS Proteomics. He then joined the Hospital for Sick Children in 2006 as the manager of the Advanced Protein Technology Centre and subsequently the SickKids Proteomics, Analytical, Robotics and Chemical Biology Centre (SPARC BioCentre). Paul has recently relocated to Rapid Novor, Inc. a company dedicated to de novo sequencing of antibodies. Paul has a total of 20 years of mass spectrometry-based proteomics research.
* Required field